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Abstract 
Delta relaxation enhanced magnetic resonance (dreMR) is a novel imaging 
method capable of producing contrast proportional only to the concentration of the bound 
form of the targetable contrast agent using a dynamic field-cycling technique. The 
characteristic high relaxivity magnetic field dependence of bound paramagnetic contrast 
agents enables suppression of tissue contrast from unbound agents and unenhanced tissue, 
thereby increasing probe specificity. The dreMR technique requires an auxiliary actively 
shielded field-shifting insert electromagnet to modulate the strength of the main clinical 
magnetic field as a function of time during the relaxation and evolution periods of a pulse 
sequence. 
Ablavar (approved for human use) binds specifically to serum albumin and has a 
strong magnetic field dependence for serum albumin around 1.5T.  Native biological 
tissues and unbound Ablavar demonstrate very little magnetic field dependence. Using a 
custom dreMR preparatory pulse, where the strength of the B0 field is modulated for 
different times, signal intensity from only the bound form of Ablavar can be produced. 
This work entails further advancement of the dreMR method, where we 
investigate developing the dreMR contrast using phantoms loaded with and without 
Rabbit Serum Albumin and in vivo imaging using mouse subjects with prostate and breast 
cancer. 
Keywords 
Ablavar, dreMR, Delta Relaxation Enhanced MRI, Field-Cycled MRI, Magnetic Resonance 
Imaging, MRI Hardware, Insert Coil, Relaxation, Relaxivity, Serum Albumin, Targeted Contrast 
Agent.
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Chapter 1 
General Introduction 
 
1.1 Magnetic Resonance Imaging 
Magnetic Resonance Imaging (MRI) is a diagnostic imaging modality that has 
steadily evolved since the 1970’s to provide unparalleled access to imaging of biological  
systems (1, 2).  MRI is non-invasive, does not deliver ionizing radiation, and provides 
excellent spatial resolution.  Its primary weakness is its low sensitivity and specificity, 
which can be improved with the use of contrast agents (1).  MRI relies on the interaction 
of nuclear spin systems with an applied magnetic field (3).  Applications and 
manipulation of various pulse sequences and magnetic field gradients provide anatomical 
images with superb soft tissue contrast.  Modern MRI techniques not only allow for 
imaging of anatomy and pathology, but also the investigation of organ function and in 
vivo biochemistry. 
 This thesis entails the development and application of a novel magnetic resonance 
(MR) molecular imaging method called delta relaxation enhanced Magnetic Resonance 
(dreMR, pronounced “dreamer”) (4).  Acting as both a device and method, dreMR uses 
field-cycling MR techniques in conjunction with clinical superconducting MRI systems to 
prepare image contrast related to the concentration of targeted contrasts agents that have 
bound to their targeted molecules. The characteristic large magnetic field dependency of 
2 
 
relaxivity (    ) of bound targeted paramagnetic contrast agents enables contrast 
suppression of unbound agents and unenhanced tissues contrast, thereby increasing the 
agents’ specificity.  The dreMR method requires additional specialized hardware to 
modulate the strength of the main clinical magnetic field to produce the dreMR contrast.  
An auxiliary, actively-shielded field-shifting insertable electromagnet is used to modulate 
the strength of the main clinical magnetic field as a function of time during the relaxation 
and evolution periods of a pulse sequence.  The introductory chapter provides the 
necessary background for understanding both MRI and the dreMR principle and method, 
introducing MRI, field-cycling relaxometry, and field-cycling MRI concepts, as well as 
the principles of relaxation of MRI contrast agents and the potential to increase molecular 
specificity with magnetic field-cycling. 
 
1.2 Principles of Magnetic Resonance Imaging 
 The basis of MRI relies on the interactions of nuclear spin systems with an 
external magnetic field.  The dominant and most commonly observed nucleus in MRI is 
the proton of the water molecule, which possesses an intrinsic nuclear spin of ½.  Nuclear 
spin is a fundamental physical property which determines if the nuclei will be observable 
by MRI.  The nuclear spin is comprised of the total sum of the individual contributions of 
both unpaired protons and neutrons, each exhibiting a ½-nuclear spin.  Only nuclides that 
possesses non-zero spin value are observable by MRI.  The spin of any nuclide is 
proportional to its magnetic moment,  , 
      (1.1) 
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where   is the gyromagnetic ratio and I is the spin quantum number.  When the magnetic 
moment is placed in an external magnetic field, nuclei with non-zero spin will 
preferentially align themselves (to a small degree) with the magnetic field, represented by 
convention along the z-axis.  When measured, (as in quantum mechanics) the magnetic 
moment will precess around the z-axis in one of two directions, parallel or antiparallel 
with the magnetic field.  Within the bulk magnetization of the spins, a little more than 
half of the spins will preferentially align parallel with the external field, the lower energy 
state, producing a small net magnetization along the direction of the magnetic field, 
illustrated in Fig. 1.1.  In the absence of a magnetic field, the magnetic moments of an 
ensemble of spins would be randomly distributed and produce a net magnetization of 
zero. 
 
Figure 1.1 Left: Magnetic moments of a spin population in the presence of an external 
magnetic field (B0).  Each magnetic moment precesses around the z-axis at the Lamor 
frequency.  Right: The spins are aligned, producing a net magnetization parallel with B0. 
 
Within the bulk magnetization, while in the presence of an external magnetic field, 
individual nuclides will precess and resonate at a specific angular frequency, called the 
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Lamor frequency.  The magnetic moment, μ, will precess around    at the Lamor 
frequency,   , given by  
       (1.2) 
 
Figure 1.2 Magnetic moment of a nuclide in the presence of an external magnetic ﬁeld 
precessing along the axis of the applied ﬁeld (z-axis) at the Larmor frequency (ω0). 
 
MRI relies on the ability to manipulate the interaction of the bulk magnetization of spins 
with the external field produced by the superconducting MR magnet. 
 
1.2.1 Signal 
An MRI signal arises from the difference in energy absorbed or emitted during 
transitions between the two spatially oriented states.  The energy of each state is given by 
Ɛ, illustrated in Equation 1.3, where I = ±½, and thus the difference between the two 
states, ΔƐ, can be calculated from Equation 1.4.  For the nuclide to transition to the higher 
energy state, Ndown (anti-parallel), sufficient electromagnetic energy, ΔƐ, must be applied.  
Similarly, for the nuclide to transition to the lower energy state, Nup (parallel), sufficient 
electromagnetic energy, ΔƐ, must be emitted to conserve energy of the spin system.  The 
ratios of the spin populations between the two orientation states, where Nup and Ndown are 
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the spin population parallel and anti-parallel to the magnetic field respectively, can be 
calculated using the Boltzmann distribution (Equation 1.5), 
 
        (1.3) 
        (1.4) 
   
     
      
  
   
  (1.5) 
 
where   is Planck’s constant divided by 2π, kB is the Boltzmann constant,  
1.3805 × 10
-23
 J K
-1
, and T is the temperature in Kelvin.  The net magnetization, M0, is 
derived from the difference between the spin orientation states, illustrated in Equations 
1.6 to 1.8. 
 
                     
    
   
                                                (1.6) 
         
      
 
 
    
   
 (1.7) 
 
   
       
    
 (1.8) 
 
The ratio demonstrates that the net magnetization varies inversely with the temperature, 
and directly with the proton density (ρ), the gyromagnetic ratio, and the applied magnetic 
field.  
In the bulk spin population, the individual spins will rotate at random phases 
around the z-axis when placed in a magnetic field.  Coherence of the spins can be 
achieved when a 90
°
 radio frequency (RF) pulse, B1, is applied at the Lamor frequency 
with a transmit RF coil.  When the application of the RF pulse is applied for a sufficient 
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duration, the net magnetization will be flipped to precess at the same phase about the z-
axis of the magnetic field in the x-y plane inducing a time varying magnetic field.  From 
Faraday’s law of induction, a voltage can be measured using an RF receiver coil sensitive 
to only the magnetization perpendicular to B0 (in the x-y plane).  The voltage signal 
detected by the receiver RF coil would be proportional to the amplitude of M0 and precess 
at the Lamor frequency.  The spins would precess about B0 until the RF field is removed, 
thereupon the spin-relaxation processes would cause loss of coherence due to dephasing 
as magnetization returns to its equilibrium position parallel to the magnetic field. As the 
spins return to equilibrium (spin-lattice relaxation), the amplitude of M0 would decay 
exponentially and produce a free induction decay (FID) signal, illustrated in Fig. 1.3. 
 
 
Figure 1.3 Coherence of spins following a 90
°
 B1 RF pulse. Left: Boltzmann distributions 
of N and Nspins in presence of magnetic field.  Middle: Following an RF pulse, the net 
magnetization is flipped into the x-y plane and precesses at the Lamor frequency.  Right: 
FID signal induced in an RF coil. 
 
1.2.2 Relaxation Times 
Immediately after the excitation of the bulk magnetization, whereby sufficient RF 
energy is applied to convert the longitudinal magnetization to the transverse plane (x-y 
plane), relaxation mechanisms act on the spin system as it relaxes back to equilibrium.  
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The two predominant features of relaxation following the RF pulse include: the dephasing 
of the spins due to differences in their precessional frequencies and magnetic field 
inhomogeneities, and the regrowth and realignment to their equilibrium orientation along 
the z-axis parallel to the magnetic field.  Following the loss of energy absorbed from the 
RF pulse, the longitudinal magnetization relaxes (spin-lattice relaxation) to the 
equilibrium orientation parallel to the z-axis of the magnetic field with a time constant   .  
At the same time, the transverse magnetization decays exponentially and relaxes (spin-
spin relaxation) with a time constant   .  The relaxation times vary with magnetic field 
strength and temperature.  The difference between the time constants,    and   , are 
important for development of contrast in MR imaging.  Biological tissues exhibit 
substantially different    and    values, and the additional administration of contrast 
agents can further enhance these values.  Generally, tissues with short    times yield 
greater signal intensity (brighter) than those with longer values due to a larger equilibrium 
magnetization (  ), and tissues possessing short    yield lower signal intensity (darker) 
due to a reduction in the detected transverse magnetization.  The MR signal from an 
image is therefore dependent on the combination of the intrinsic tissue properties and 
extrinsic user-selected imaging parameters and contrast agents.  The choice of specific 
pulse sequences with optimized parameters can be used to exploit tissues contrast and 
improve image quality. 
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Figure 1.4 Longitudinal (  ) and Transverse (  ) relaxation rate curves.  (Adapted from 
McRobbie, DW. 2007).  
 
1.2.3 Longitudinal Relaxation Time, T1 
At equilibrium, the bulk magnetization produces a net magnetization,   , parallel 
with the external magnetic field,   .  The longitudinal (  ) relaxation, also known as 
spin-lattice relaxation, is described as the re-establishment of the equilibrium longitudinal 
magnetization   , along the z-axis following the application of a 90
°
 RF pulse.  The    
relaxation process, results in a loss of the absorbed RF energy to the spin system and the 
surrounding environment (lattice).  The relaxation process emerges from the fluctuations 
in the local magnetic field due to the interactions between the spins and their environment 
as the molecule tumbles.  The    relaxation time is given by Equation 1.9, and is 
described as the time, , needed for z-component of the magnetization to recover to 63% 
of   (Fig. 1.4). 
          
  
     (1.9) 
 
   times can be accurately measured by a simple NMR technique where 
sequential 90
°
 RF pulses are applied with changing delay times, τ, in-between to examine 
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the    recovery (Fig. 1.5).  Repeating the sequence for multiple delay times, the    time 
can be determined by plotting the area under the FID versus τ, and fit with an 
exponentially decay function to extract the time constant    (5). 
 
Figure 1.5 The Longitudinal Relaxation Experiment. 
 
1.2.4 Transverse Relaxation Time, T2 
In the same time that    relaxation occurs, where    recovers to equilibrium, the 
transverse magnetization,    , decreases exponentially due to the dephasing of spins 
throughout the spin systems.  The transverse (  ) relaxation, also known as spin-spin 
relaxation, occurs following the application of a 90
°
 RF pulse, where the spins dephase 
due to differences in their precessional frequencies.    
  relaxation occurs immediately 
following a 90
°
 RF pulse, whereas    relaxation occurs following 90
°
-180
°
 sequential RF 
pulses (also known as a spin echo sequence).  The combined effects of the imperfections 
in the main magnetic ﬁeld and the spin-spin interactions lead to the transverse 
magnetization decay.  The relaxation process emerges from the molecular size and 
mobility of the tumbling molecules, where fast tumbling mobile molecules are able to 
average out the field inhomogeneities and intrinsic spin dephasing (leading to longer    
times), and large slow tumbling immobile molecules readily experience spin interactions 
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and field inhomogeneities (leading to shorter    times) (2, 5).  The    relaxation time is 
given by Equation 1.10, and is described as the time needed to recover to 37%      
     of   (Fig. 1.4). 
        
  
    (1.10) 
 
   times can be accurately measured by a simple NMR technique where 
sequential 90
°
-180
°
 RF pulses are applied with changing delay times, τ, in-between to 
examine the     decay (Fig. 1.6).  The initial 90
°
 RF pulse flips the net magnetization 
onto the transverse plane, where the spins begin to dephase at the Lamor frequency.  The 
subsequent application of the 180
°
 RF pulse refocuses the spins and forms an echo, 
allowing for detection of the FID signal.  True    decay however is determined from 
multiple 180
°
 refocusing pulses, where the transverse signal will decay with the    time 
constant and can be determined by plotting the data points from the decay curve (5).  The 
single FID signal acquired from one 90
°
-180
°
 RF pulse decays with a   
  decay constant, 
which is dependent on the magnet and its field imperfections. 
 
Figure 1.6 The Transverse Relaxation Experiment. 
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1.3 Contrast Agents 
The contrast from MR images can be manipulated by changing the intrinsic 
biological tissues relaxation processes or the extrinsic user-selected pulse sequence 
parameters.  The driving force for the use of contrast agents in MRI is to further enhance 
and/or differentiate signals arising from the biological tissues of interest.  In the clinical 
practice, approximately 35% of all MRI examinations are performed with contrast  
agents (6, 7).  Contrast agents are pharmaceutical drugs that directly affect the magnetic 
properties of water protons within their vicinity by increasing the protons’ relaxation 
rates.  Contrast agents are administered intravenously and exhibit properties such that 
they are highly soluble, well-tolerated, and chemically inert (chelated metal ions), and are 
rapidly eliminated from the body following the examination (8).  The majority of contrast 
agents are chelates containing either Gd(III), Fe(III), Mn(II), or iron oxide ions (7-9).  
Paramagnetic (Gd(III), Fe(III), Mn(II)) contrast agents predominantly accelerate the    
relaxation process, resulting in positive signal enhancement, while superparamagnetic 
(iron oxide) contrast agents predominantly accelerate the    relaxation process, resulting 
in negative signal enhancement (10).  Gadolinium(III) is the most used and studied metal 
ion for use in MRI because of its seven unpaired electrons and ideal structural symmetry 
(8, 11).  Due to the large molar concentrations required to allow for sufficient proton 
relaxation (10 -100 μM) (9, 12), the metal ion complex must be chelated to reduce acute 
and chronic toxicity and increase in vivo stability and excretability (9).  Recent 
developments have seen the ability to modify the chelating agent to increase target 
specificity by including selective binding biological vectors (7, 13).   
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In addition to the signal enhancement classiﬁcation (   vs    action), all contrast 
agents can be divided based on their site of action: extracellular, organ-speciﬁc, or 
intravascular agents (10).  Extracellular contrast agents distribute non-specifically 
throughout the plasma and interstitial space of the body (8), organ-speciﬁc contrast agents 
accumulate specifically in the targeted organ, and intravascular agents enhance the 
arterial and vascular structure for the period of the MRI exam (12).  Historically, 
development of contrast agents have been focused on   -based contrast agents, since the 
   relaxation times are typically ﬁve times longer than T2 and therefore easier to shorten 
(8, 10). 
 
1.3.1 Relaxivity 
The largest challenge in MR imaging is its relatively low sensitivity.  As a result 
of the high concentration of commercial contrast agents (millimolar concentration) 
required to affect the relaxation rates of protons, there have been great efforts to increase 
the contrast sensitivity (8).  The ability of a contrast agent to change the relaxation rate is 
characterized as its relaxivity,   .  Relaxivity is defined as the efficiency with which the 
contrast agent enhances the proton relaxation rates (9). 
 
    
                    
    
            (1.11) 
 
where Ri is the inverse of the relaxation time, 
 
  
, known as the relaxation rate, and [CA] is 
the concentration of the contrast agent on a per Gd(III) basis.  High relaxivity agents can 
be detected at lower doses and provide greater contrast at equivalent doses to current 
commercial agents with lower relaxivity (1, 8, 14).  The two approaches to increasing the 
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relaxivity of contrast agents are to either increase the intrinsic molecular parameters that 
govern their relaxivity or to attach multiple metal (generally Gd(III)) ions within the 
complexes (1, 9).  Attaching multiple metal complexes together to the molecular structure 
increases the agents’ relaxivity by reducing the molecular tumbling, τr, due to an increase 
in molecular size.  The interaction between the Gd(III) and the water molecules becomes 
more efficient by reducing the molecular tumbling, τr thereby increasing the effect on 
local relaxation rates (13). The intrinsic molecular parameters that govern relaxivity 
include hydration number, q, the distance between the Gd(III) ion and the water proton, 
the water exchange rate, the electronic relaxation time,    , and the rotational correlation 
time,   . (11, 15).  Relaxation rates of water protons under the influence of Gd(III) are 
largely dominated by inner-sphere relaxivity, resulting from the dipolar contributions due 
to interactions with random fluctuations of the electronic field (15).  The longitudinal 
relaxation arising from the inner-sphere relaxation can be modeled using a modified 
Solomon-Bloembergen-Morgan equation formulated by R. Lauffer (9) given by  
 
  
   
 M 
  2  
   
      
 (1.11) 
 
where [M] is the molar concentration of the paramagnetic ion, [H2O] is the molar 
concentration of water, qIS is the inner-sphere hydration number , T1M is the relaxation 
time for bound inner-sphere water molecules and τm is the water residency time.  Inner-
sphere relaxation is inversely proportional to the metal-ion-proton distance to the 6
th
 
power. Achieving a reduced distance between the Gd(III) ion and bound protons in 
principle would increase relaxivity, since the inner-sphere relaxation is inversely 
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proportional to the metal-ion-proton distance to the 6
th
 power.  Reducing the metal-ion-
proton distance would also allow for rapid exchange between the bound protons and the 
free water and efficiently distribute the relaxation effects (1, 11). All commercially 
approved Gd(III) contrast agents have one inner-sphere binding site, qIS, for water 
protons.  The ability to increase qIS would increase relaxivity, as they are linearly 
proportional, however contrast agents that allow multiple binding sites for protons in their 
first coordination sphere experience reduced stability and increased concerns for toxicity 
(14).  The rotational correlation time,   , is largely dependent on the molecular tumbling 
correlation time,   , the electronic relaxation time,    , and the chemical exchange,   .  
Field strength, molecular structure, and the biochemical environment dominate the 
efficiency of these time constants and contribute to the overall chemical exchange 
between the contrast agent, water proton, and bulk protons (1, 6, 14).  Essentially, the 
contrast agent must be stable and chemically inert, allow for fast water exchange from the 
first coordination sphere, and efficiently relax the protons it contacts. 
 
 
Figure 1.7 Parameters influencing relaxivity. (Adapted from Hermann, P et al., 2008). 
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1.3.2 Targeted Contrast Agents  
The development of targeted contrast agents involves optimizing both their 
affinity and speciﬁcity for its protein target (8).  The challenge of synthesizing 
compounds with both high target afﬁnity and relaxivity is an ongoing field of interest in 
medical chemistry (12).  With the large micromolar doses required for sufficient contrast 
enhancement, current agents are limited to sites where accumulations of high 
concentrations are expected.  Detection at the cellular and/or sub-cellular level would 
require nanomolar sensitivity, so that conventional Gd(III) agents are suitable (16).  New 
generations of contrast agents are being developed to be site-specific and with increased 
tissue specificity, and as a result, higher relaxivities are required to compensate for the 
decrease in concentration needed to detect cellular and sub-cellular bioactivity (1, 6, 15-
17). 
Targeted contrast agents are defined by their mechanism of action, targeting either 
passively or actively.  Passive targeting favours the specific distribution characteristics of 
tissues and cells and are generally either phagocytosed by macrophages or incorporated 
into components of the mononuclear phagocyte system (11, 13, 18).  Active targeting 
selectively binds to molecular targets expressed within various diseases models including  
cell surface markers on immune cells or speciﬁc markers speciﬁcally expressed  in certain 
stages of disease (11, 13, 18).  Synthesizing compounds for targeted binding (through 
proteins, antibodies, or small peptides) improves relaxivity by slowing down the tumbling 
rate of the agent, thereby improving the agents’ specificity.   owever the binding process 
is not always an effective strategy since binding to a large biomolecule can also alter the 
hydration number and water exchange rate within the inner-sphere (11) reducing the 
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inherent relaxivity of the agent.  The challenges to maintain and/or improve the agents’ 
relaxivity upon binding to their target biomolecule is evident by the limited number of 
contrast agents approved for clinical use with MRI by the Food and Drug Administration 
(FDA), European Medicines Agency (EMEA), and Health Canada.  In addition to the 
large target affinity, targeted contrast agents exhibit a strong relaxivity change in 
magnetic field dependence in both their targeted and non-targeted states (1, 6, 8-12, 14, 
15, 17-21).  Ablavar (Gadofosveset trisodium, (formerly known as MS-325 and Vasovist) 
Lantheus Medical Imaging, Inc. N. Billerica, MA, USA) binds to serum albumin and is 
the only current clinically available targeted MRI contrast agents available on the market.  
EP-2104R (EPIX Pharmaceuticals, Lexington, Massachusetts, USA) binds to fibrin (21), 
and is currently undergoing clinical phase trials.  Ablavar differs from other polymeric 
Gd(III) complexes, most notably Albumin-GdDTPA.  Albumin-GdDTPA, bound 
covalently to albumin, was a prototypical intravascular blood pool contrast agent that 
promised favorable contrast for vascular imaging; however, it was not approved for 
clinical use due to its poor stability, renal excretion rates, and low water solubility (7). 
Albumin and fibrin are useful targeting moieties due to their micromolar 
concentrations, and specific pathological presence that can aid in specificity (19, 21).  The 
most abundant protein in the blood plasma at concentration of 600-700 μM, albumin 
reversibly binds noncovalently with Ablavar to provide enhanced    contrast (19).  The 
reversible binding to albumin controls the leakage of the contrast agent to the 
intravascular space, allows for the nontargeted fraction to be filtered through excretion to 
the kidneys, protects the targeted fraction from filtration, and increases the agents’ 
relaxivity approximately 10-fold at 20 MHz (for HSA) upon binding to the larger albumin 
molecule (67 kDa) (19, 20).  Ablavar has moderate affinity for HSA, with reported 
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circulating concentrations of 0.1 mM, 88% of the administered Ablavar is noncovalently 
bound to HSA (19, 20), and in vivo studies have shown strong enhancement 1-hour post 
injection for animals and 24 hours for humans(19, 20).  Originally used to measure liver 
function, nutritional status and diseases (Kawasaki, Pancreatitis) (22), recent evidence has 
shown albumin as a marker for angiogenic blood vessels presenting a major role in tumor 
microenvironment trafficking in and out of tumors, (23-26). 
The high sensitivity and specificity of targeted contrast agents makes them 
advantageous for molecular imaging, however a major concern with regards to MRI not 
readily experienced in other imaging techniques (nuclear, optical), is the enhanced signal 
present from tissue in the vicinity of unbound agent and even signal from unenhanced 
background tissue (18).  The issue is complicated by the high level of competing signal 
from all three instances (18).  The signal arising from the unenhanced background tissue 
can be suppressed by scanning pre and post agent administration, however this of course 
requires two imaging scans and enough time for the agent to distribute and accumulate in 
vivo.  Unfortunately, it becomes highly problematic when trying to distinguish targeted 
from non-targeted contrast agents since even with the high relaxivity enhancement in the 
targeted complex, the signals arising from both cases are indistinguishable.  It is 
understandable that combining the advantages of MRI, which provides high-resolution 
anatomical images, with molecular sensitivity within a single imaging system would 
greatly aid and possibly simplify the process of detection of diseases.  This was the basic 
premise of the dreMR: by exploiting the relaxivity magnetic field dependence possessed 
by only the bound form of the targeted agent, one could suppress both signal arising from 
the non-targeted contrast agent and unenhanced biological tissues, and only obtain signal 
arising from the targeted contrast agent (4, 27, 28).  Novel relaxometry data published by 
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Koenig et. al. (Fig. 1.8), demonstrated the relaxation rate magnetic field dependence for 
six tissues in a rat.   
 
 
Figure 1.8 The relaxation rates of various rat tissues, at 30 , as a function of magnetic 
field strength.  (Reprinted with permission: Koenig SH, Brown RD, 3rd, Adams D, 
Emerson D, Harrison CG. Magnetic field dependence of 1/T1 of protons in tissue. 
Investigative Radiology. 1984;19(2):76-81) (29). 
 
At lower magnetic field strengths, there is a large variation in the relaxation rate 
magnetic field dependence; however the relaxivities for all tissues begin to converge as 
the magnetic field strength increases above 0.1 T, minimizing the field dependence.  A 
more important observation is that as the magnetic field strength approaches clinical field 
strength (>1 T), the change in   , 
   
  
, approaches zero for all tissues.  Comparing the 
strong relaxivity magnetic field dependence of the targeted contrast with the minimal 
dependence of non-targeted contrast agents and unenhanced biological tissues, it becomes 
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apparent that signal arising only from the bound form of the targeted agent can be 
discriminated by modulating the magnetic field within a clinical MRI scanner. 
 
1.3.3 Field Strength, B0, and Temperature Dependence 
The relaxivity field dependence is an essential parameter to consider during the 
development and optimization of contrast agents, whether they are non-specific or 
targeted.  Longitudinal and transverse relaxivities are strongly field dependent over 
limited ranges.  As the applied magnetic field increases, the field dependence decreases 
for longitudinal relaxivity since the relaxation rates of the contrast agent and solvent 
converge (observation is reversed for transverse relaxivity) (1, 6, 14, 29).  With the 
general trend towards higher fields in MRI, (3 T and beyond), to increase both sensitivity 
and resolution, the commensurate decrease in agent relaxivity reduces much of the 
potential gains (11, 29).  An increase in field strength would also amount to an increase in 
tissue relaxation rates, suggesting contrast between normal and abnormal tissue will be 
field dependent as well (29).  Water exchange rate, rotational diffusion, and correlation 
time, parameters governing relaxivity, are all temperature dependent, all increasing with 
temperature (1, 14, 17).  It becomes necessary to understand the parameters governing 
both the relaxivity and relaxation times field dependence of the contrast agents and 
tissues to choose an optimal field for imaging, factors that impact whether the contrast 
agent will become clinically relevant (1, 6, 11, 14, 17, 29). 
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1.4 Field-Cycling Relaxometry 
Conventional MRI uses a high-field superconducting magnet to both polarize and 
image (with the use of gradients systems and RF coils) the nuclei of an object, producing 
contrast from the relaxation properties (exploited by pulse sequences) of tissues.  A field-
cycling relaxometer directly measures the relaxation rates of samples by modulating the 
strength of the magnetic field during a series of magnetization evolution periods (30-32).  
The basic premise of ﬁeld-cycling magnetic resonance is the ability to rapidly switch 
between magnetic strengths for relaxation and signal acquisition levels during the pulse 
sequence without causing artifacts or image degradation due to the fast switching for 
acquisition (30).  Field-cycling of the magnetic field permits acquisition at one field 
strength so that a series of relaxation measurements at different field strengths can be 
obtained at a single acquisition field without re-tuning the NMR probe. The acquisition 
field is chosen predominantly to maximize signal strength. 
As depicted in the general pulse sequence (Fig. 1.9), the sequence consists of three 
periods for which the magnetic field is switched and varied: the polarization (  ), the 
relaxation (  ), and the detection (  ) fields.  The initial polarization field serves to 
increase the Boltzmann nuclear magnetisation of the spin system, the relaxation field 
serves to allow the spin system evolve for a specified duration and relax, and finally the 
detection field serves to detect the resulting FID signal.  An extended recycle delay is 
implemented to allow the resistive magnet system to rest before the next cycle, 
establishing a thermal equilibrium for magnet and power supply.  Continuing the 
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sequence for a series of relaxation field strengths, one can generate a nuclear magnetic 
resonance dispersion curve for the relaxation times of the sample. 
 
 
Figure 1.9 Typical field-cycling relaxometry pulse sequence (Adapted from Kimmich et 
al., 2004).  The recycle delay (zero field) has been omitted. 
 
The preferred technique for field-cycling relaxometry consists of studying the field 
dependence of relaxation times (or rates).  Studies employing the field-cycling technique 
have been regularly used to measure material properties, contrast agents and fluid 
interfaces, and biochemical interactions (32, 33).  The evolution towards medical 
applications was predicated on the field dependence of normal and abnormal tissues, 
greatest at low field strength (< 0.4 T), ranging from 1 μT to 1.5 T (29, 31, 33-36).  
Relaxometry studies have shown field dependencies of various tissue diseased states, 
most notably of interest, Parkinson’s and human brain cancers (29, 36-38).  Applying 
field-cycling techniques to imaging would expand the ability to derive contrast from 
normal and abnormal tissues. 
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1.4.1 Field Cycling Magnetic Resonance Imaging 
Conventional MRI is a multi-parameter imaging method that requires a stable, 
constant, homogenous magnetic field throughout the imaging process.  Field-cycling MRI 
combines the techniques of field-cycling relaxometry with the imaging methods of MRI, 
offering access to biological information not available from conventional clinical imaging 
(39).  Field-cycling MRI uses pulse sequences that differ from conventional MRI.  During 
field-cycling MRI sequences, the magnetic field strength is modulated several times 
before signal detection by varying the current flowing through a resistive magnet that is 
inserted into the MRI bore or resistive-permanent magnet hybrid (33, 39).  In this manner, 
the spin system evolves and relaxes at different relaxation fields to exploit the relaxivity 
field dependence, before returning to the scanner’s usual field strength for signal 
detection.  Field-cycling MRI alludes to measuring biophysical parameters by decoupling 
different contrast mechanisms (relaxation times) contributing to the MR signal (40-43).  
By exploiting the disparate magnetic field dependence of relaxivity for targeted contrast 
agents and unenhanced biological tissues with dreMR, new biophysical contrast 
parameters can be measured.   Assessment of tumors, liver disease, and disorders of the 
brain, kidney, spleen, and pancreas would beneﬁt from the quantitative measurements of 
field-cycling relaxometry and imaging (29, 32, 40, 42).  The trade-off of field-cycling 
imaging over conventional MR imaging involves compromises such as increased imaging 
time, decreased spatial resolution and image quality regulated by reduced SNR.  
Implementation of this method has several technical challenges, which were investigated 
as part of this research.  Interactions between the clinical and field-cycling magnet 
systems can lead to image artefacts resulting in misinterpretation of the biophysical 
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parameters (33, 34, 42).   Careful construction of the field-cycling insert magnet including 
an accurately designed active magnetic shield and computer-controlled eddy current 
compensation has eliminated to a large extent almost all artefacts.  With these technical 
challenges under control, this novel imaging contrast has been investigated to optimize 
various system and imaging parameters for comparison with conventional MR imaging.  
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1.5 Thesis Objectives and Overview  
The work present in the thesis was completed by me in the Imaging Research 
Laboratories of the Robarts Research Institute under the supervision of Dr. Timothy 
Scholl as a Master’s candidate in the Department of Medical Biophysics at Western 
University.  This research involved a collaboration between the groups led by Dr. Scholl 
and Dr. Blaine Chronik in the Department of Physics and Astronomy at Western 
University.  This included substantial assistance from Dr. Francisco Martínez-
Santiesteban (Scholl Group), Dr. William Handler (Chronik Group) and graduate student 
Mr. Chad Harris (Chronik Group).  Many of the original ideas, which form the basis of 
dreMR were developed by Dr. Jamu Alford, a former Chronik graduate student and Dr. 
Brian Rutt (formerly at the Robarts Research Institute, presently at Stanford University). I 
also wish to acknowledge the input of Dr. Peter Caravan (Harvard University) who was 
the original developer of Ablavar and his research assistant, Dr. Christian Farrar, who 
have provided many helpful discussions. The overall goal of this project was to use Delta 
Relaxation Enhanced Magnetic Imaging to assess the albumin uptake in tumours in 
clinically relevant murine cancer models using the targeting MRI contrast agent Ablavar. 
Specific objectives included: 
1) Use of field-cycling relaxometry techniques to measure and characterize the 
relaxivity of Ablavar 
2) Application and integration of the new dreMR hardware and pulse sequence for 
dreMR imaging 
3) Examination of Albavar-albumin binding using dreMR imaging to distinguish 
only the targeted form of the contrast agent. 
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Chapter 2 discusses the development and application of the field-cycling 
relaxometry techniques to measure the relaxivity of Ablavar, the implementation of the 
new dreMR hardware, pulse sequences, and the integration with the clinical MRI scanner.  
Chapter 3 presents the experimental findings and the resulting dreMR images from the 
single inversion and double inversion pulse sequence using both phantoms and in vivo 
murine cancer models.  Chapter 4 summarizes the key experimental findings and the 
significance and implications of dreMR imaging.  Current limitations and future 
directions to improve dreMR imaging are also discussed. 
The samples for Ablavar-albumin relaxation rates measurements were prepared by 
me.  Their measurements and relaxivity data analysis were completed by me and Dr. 
Martínez-Santiesteban, with guidance from Dr. Scholl.  The relaxivity modeling using the 
Lauffer Model of Relaxivity was provided by Dr. Scholl.  Dr. Alford and Mr. Chad Harris 
provided the electromagnetic simulation models for the dreMR insert coil and the active 
shield.  The construction of the dreMR insert coil was completed by Mr. Frank Van Sas 
and Mr. Brian Dalrymple under the supervision of Drs. Scholl and Handler.  Mr. Harris 
and I provided assistance during the construction process.  The National Instruments 
control software was provided by Dr. Handler.  The modified Triple Inversion Recovery 
MRI pulse sequence was provided by Dr. Jeff Stainsby (GE Healthcare).  The solid state 
switch box was previously built by Dr. Alford and Mr. Doug Hie (Physics and Astronomy 
Electronics Shop).  The gradient amplifier was installed and matched to the dreMR coil 
by Joseph Venditto (Performance Controls Incorporated).  I built the RF birdcage coil 
with assistance and feedback from Patrick Lim.  The breast and prostate cancer models 
were provided by Dr. Paula Foster and her students Ms. Vasiliki Economopoulos and Ms. 
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Christiane Mallett.  I was responsible for animal preparations during the in vivo dreMR 
studies, with assistance from Dr. Emeline Ribot for the mouse tail-vain catheter.  The 
water heated mouse anaesthesia bed was designed by Dr. Scholl, and built by Misters Van 
Sas and Dalrymple.  Drs. Scholl, Handler, Martínez-Santiesteban, Mr. Harris, and I 
participated in the imaging sessions and image analysis.  The phantom and in vivo dreMR 
images were processed and analyzed by me. Finally, Dr. Scholl, as principal author’s 
supervisor, provided guidance and mentorship, helped determine the overall thesis 
objectives, reviewed project results, and provided editorial assistance with the thesis 
manuscript.  
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Chapter 2 
Construction, Design and Methods for dreMR 
Experiments 
The ability to prepare and derive image contrast related to the concentration of 
only the bound targeted contrast agent requires additional specialized hardware that must 
be added to a clinical superconducting MRI system.  For ordinary magnetic resonance 
imaging, contrast enhancement is achieved using pulse sequence parameters and contrast 
agents that take advantage of the relaxation properties of the tissues of interest.  This 
process unfortunately suffers from competing signal arising from unenhanced tissues and 
enhanced tissue from the contrast agent in its targeted and non-targeted states.  To 
identify the image contrast from only the targeted agent, one would be required to scan 
pre and post contrast agent administration. This method does not discriminate between 
tissues enhanced by bound or unbound contrast agent; however with dreMR imaging, 
contrast agents bound to their target can be directly imaged eliminating the need for 
baseline imaging. dreMR imaging uses field-cycling MR techniques to modulate the 
strength of the main clinical magnetic field to produce the contrast enhancement only 
from the targeted form of the contrast agent.  The dreMR method can be simply described 
as a actively shielded    insert coil within an unmodified clinical superconducting MR 
system, controlled by additional supportive hardware and software to prepare sample 
magnetization for standard MR imaging.  For this purpose, a redesigned 2
nd
-generation 
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dreMR coil was constructed specifically for small animal imaging (mouse-sized), to 
include improvements in mechanical, electrical and thermal design (44, 45). 
 Chapter 2 forms the basis of the design, construction and hardware improvements 
to the dreMR insert coil and the supplemental hardware and software.  The fundamentals 
of the dreMR coil are described, as well as the required hardware and software sequences 
to perform dreMR imaging.  The supplemental hardware and software include the fast 
current switch box to isolate the dreMR coil from the MR scanner during image 
acquisition, the power amplifier to drive the dreMR coil, the control systems hardware 
and software for integration and synchronization with the MR scanner, the RF coil, and 
the modified Triple Inversion pulse sequence with the dreMR magnetic field shifting 
preparation stages.  All of the equipment was tested offline (outside the MR scanner 
room) before integration with the scanner to insure proper operation and to protect 
personnel and equipment. Preparations for the phantom and animal models are discussed, 
as well as the MRI acquisition and the image processing required to produce the dreMR 
images. The field-cycling relaxometry measurements and preparations of the Albavar-
albumin concentrations is presented, including the Lauffer Model of Relaxivity, to 
demonstrate how the dreMR contrast is derived from the relaxivity magnetic field 
dependence of the Albavar-albumin complex. 
2.1 Improvements to dreMR B0 Insert Coil and Hardware 
In its fundamental form, the dreMR insert coil must produce nearly uniform field 
shifts (> 0.1 T) within milliseconds without disrupting the stability of the host scanner 
and withstand the potential torques and forces as a result of Lorentz forces.  To produce 
the desired uniform magnetic field shifts and minimize coupling interactions with the host 
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MRI scanner, the auxiliary insert coil needed to observe specific design criteria, 
specifically force and torque balancing, magnetic field homogeneity, inductance and 
ramping timings, heat dissipation through efficient cooling, and perhaps most 
importantly, magnetic coupling with the host MRI scanner. 
 
2.1.1 dreMR B0 Insert Coil 
 The dreMR insert coil is not directly involved in the process of imaging the 
sample, but rather acts to specially prepare sample magnetization before imaging with the 
host MRI scanner.  The dreMR insert coil produces magnetic field shifts for tissue 
magnetization and then is turned off during signal acquisition.  As a result, the 
homogeneity requirement for dreMR is much less than for the clinical magnet.  Field 
calculations based on the electromagnetic designs indicate that inhomogeneity over a 20-
mm-diameter, 40-mm-long-cylinder is 1.5% (approximate imaging volume of a mouse).  
This limited inhomogeneity has only a very limited affect on dreMR contrast producing 
an unnoticeable shading.   
The requirement to repetitively ramp the magnetic field (on the order of 
milliseconds) on and off has the potential to produce eddy-currents capable of inducing 
instabilities in the main field that persist throughout signal acquisition, most notably 
phase and slice select artefacts.  The dreMR insert coil was composed of two concentric 
electromagnets, a small solenoid primary coil for producing the magnetic field shifts and 
a counter-wound shield coil to largely eliminate the insert’s fringe fields and coupling 
with the host MRI scanner.   
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Previous design calculations, methods, materials, and constructions techniques 
have been described (44, 46, 47); however, efforts have been made to improve the 
construction of the active shield for this newest device (45).  There were inherent 
practical errors related to methods of construction and winding for the first-generation 
dreMR insert coil, such that the final constructed coil deviated from the original 
theoretical design.  For example, subtle twisting of the magnet windings for the primary 
solenoid causing positional variations in both the longitudinal and radial wire locations 
compared with the ideal electrical design.  This, in turn led to an accumulation of these 
small variances eventually causing a net misplacement of the entire coil on the former 
bobbin.  The construction protocol was adapted to minimize the inherent winding errors 
and create a more realistic model of the primary coil.  During winding, a wire 
“straightener” was used to remove small bends from the square hollow copper wire (5-
mm width, 3-mm hole diameter) prior to winding onto a cylindrical G-10 former to create 
the primary coil (6 radial layers, 30 wire turns per layer, 15 turns per half, inner diameter 
of 8 cm, and length of 17 cm) (45).  In addition, the actual positions of each individual 
wire loop were measured at each solenoid layer and used in a final design of the active 
shield. (45).  The resulting single-layer shield wire pattern was counter-wound onto a 
second cylindrical G-10 former with diameter and total length of 28.8 cm and 30.5 cm 
respectively. 
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Figure 2.1 dreMR insert coil. Top row: Left: Schematic drawing of the dreMR coil 
(provided by Dr. Scholl).  Middle: Winding process of dreMR insert coil with wire 
straightening apparatus.  Right: Misalignment of wire patterns (top) from original 
winding construction protocol, and example of measurement of wire positions after one 
winding layer of the primary coil (bottom). Bottom Row: dreMR coil on the patient bed 
inside MR scanner.  The RF coil and water-heated mouse anaesthesia bed are placed in 
front of the dreMR coil to show their integration.  
 
Estimates of improved shielding due to the inclusion of measured wire positions 
for accurate calculation of the active shield geometry suggest gains in shield effectiveness 
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of better than 15%.  Specifications for the second-generation dreMR B0 insert coil, 
designed for mouse imaging include a cylindrical imaging region approximately 5-cm 
long and 2.5-cm in diameter. Physical parameters are: 42-cm length, 8-cm inner diameter, 
32-cm outer diameter and 50-kg mass.  Electrical parameters include 1.46-mH 
inductance, 96.4-mΩ resistance and 0.8697-mT/A magnetic field efficiency (44, 45). 
 
2.1.2 Gradient Amplifier and Control 
The shielded dreMR    insert coil was powered by a QDCM 700 series gradient 
amplifier (Performance Control Inc., PA, USA).  The internal feedback circuit of the 
gradient amplifier was calibrated to match the inductance (1.46 mH) and resistance (96.4 
mΩ) of the dreMR insert coil, ensuring the gradient amplifiers faithfully reproduced the 
input waveforms generated by the National Instruments control hardware (NI DAQ).  The 
NI DAQ was controlled by custom software written in LabView (National Instruments, 
version 11.0) running on a separate laptop computer.  Waveform synchronization 
between the NI DAQ and the MRI console was realized by means of a transistor-
transistor logic (TTL) trigger generated by the MRI system electronics initiated by the 
modified pulse sequence.  The gradient amplifier and NI DAQ were housed in the MRI 
electronics equipment room, and communication between the NI laptop software and NI 
DAQ were performed via a 20-m long unshielded fiber-optic Universal Serial Bus (USB) 
cable to limit potential electromagnetic noise. 
Notable specifications for the bipolar dual-axis gradient amplifier included peak 
output current of 430 A for 20 ms, peak output voltage 725 V, output current 270 A rms 
over a 300-s averaging window, 200 A rms for greater than 300 s, and a risetime to 
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maximum current of 300 μs.  From these specifications, it was possible to reliably 
achieve a maximum constant magnetic field shift of 375 mT over a 300 s scan and 
maximum slew rate of 400 T/s with the dreMR B0 coil. 
 
Figure 2.2 dreMR gradient amplifier positioned next to MR scanner hardware in the 
scanner equipment room. 
 
2.1.3 Current Switch Box 
The dreMR field homogeneity (~1.5%) is modest compared to that of the host 
scanner.  This is not a limitation since the field is nominally zero during the image 
acquisition.  However, small current offsets or fluctuations from the gradient amplifier 
powering the dreMR magnet can cause significant image artefacts due to the high field 
efficiency of the magnet system (0.8697 mT/A).  A switch is therefore required to 
disconnect the dreMR from the gradient amplifier during image acquisition.  The gradient 
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amplifier is designed to drive inductive loads.  Its control circuitry supplies a current 
through the load that is proportional to an input voltage.  Even when the input voltage is 
nominally zero, small offsets present anywhere along the input chain or in the amplifier 
circuitry are sensed and converted to a small output current.  In the absence of a 
connected load, this will drive the amplifier outputs to maximum voltage.  An auxiliary 
load with an inductance that is similar to that of the dreMR electromagnet to prevent 
current feedback oscillations must be substituted when the dreMR insert coil is isolated 
from the current source.  A solid-state fast switch box was used to switch to an auxiliary 
“dummy load” (an inductor and power resistor in series chosen to match the electrical 
characteristics of the dreMR electromagnet, labeled bypass coil in Fig. 2.4) when the 
dreMR insert coil was deactivated during image acquisition.  Design and construction of 
the fast switch box had previously been described (4) such that either the dreMR insert or 
the dummy load was attached to the amplifier at all times to prevent runaway current 
oscillations from damaging the amplifier.  The switch box circuit contained two custom-
built solid-state sub-switches, each with two 400-A 1200-V insulated gate bipolar 
transistors (IGBT) (POWEREX 400HA-24A), biased with an optically-isolated driver 
circuit (POWEREX BG2A-NF), and two 300-A 1200-V diodes (POWEREX CS641230).  
Bipolar current waveforms were achievable with the two separate IGBT current 
pathways.  The high-current diodes prevented reverse current from overloading the 
protection diode in the transistors while in their off non-conducting state.  Product 
specifications for IGBT and diode specified a continuous maximum peak current was 300 
A with a 800-ns switching time for the diode, and a maximum peak current was 800 A 
with a 600-ns time for the IGBT.  The fast switch box circuitry and dummy solenoid load 
were mounted on a 19-inch-wide 1000-W fan-cooled heat sink (TW7-1275-flsx, D6 
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Industries, Massachusetts, USA) to prevent overheating.  Temporal control of the fast 
switching circuitry was achieved with TTL signals from the NI DAQ hardware 
synchronized to the pulse sequence. 
 
Figure 2.3 The current switch box disconnects the dreMR from the gradient amplifier 
during image acquisition.  The switch box switches to an auxiliary load when the dreMR 
insert coil is deactivated during image acquisition to remove any offset currents and 
noise.  Right: Picture of the current switch box.  Left: Schematic of the integration of the 
current switch box with the gradient amplifier, dreMR coil and bypass coil (Adapted from 
Alford., 2009). 
 
2.1.4 Radiofrequency Coil 
 A custom highpass, capacitively-matched, cylindrical eight-rung birdcage RF 
coil was built for the second-generation dreMR insert coil.  The RF coil was to tuned to 
the proton Lamor frequency at 1.5 T (63.86 MHz) with an imaging volume of 5 cm.  The 
RF coil was shielded with a 150-μm stainless steel mesh cylindrical shield to reduce noise 
and coupling with the dreMR insert coil.  The RF coil was securely attached with an 
extended arm screwed into the exterior of the dreMR insert coil to prevent RF coil 
movement during the magnetic field shifting produced by the dreMR insert coil.  The 
same RF coil was used throughout all phantom and in vivo imaging sessions.   
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2.2 dreMR Integration with Scanner 
The dreMR imaging method requires custom software to implement the field 
shifting required to exploit the relaxivity field dependence of the targeted contrast agents 
and tissues.  The dreMR pulse sequence consists of two parts: a preparatory stage, and an 
imaging stage.  The dreMR insert coil was activated during the preparatory stage to 
provide the required field shift for magnetization of the spin systems and then deactivated 
during the imaging stage.  Precise synchronization of the dreMR insert coil and MRI 
console was an integral component to acquire meaningful contrast and images that were 
free of artefacts.  The dreMR insert coil was controlled by a NI DAQ system executing 
custom software in LabView (National Instruments Corp. USA) by a separate laptop 
computer in the MRI console station.  The custom software is summarized in section 
2.2.1.  Synchronization was achieved by a TTL trigger generated by the MRI system 
electronics during the pulse sequence. 
2.2.1 Pulse Sequence 
The dreMR pulse sequence was based on a standard imaging sequence known as 
the Triple Inversion Recovery, controlled by the Blood Suppression imaging option, on a 
GE Healthcare 1.5 T CVMR scanner (WI, USA).  The Triple Inversion Recovery pulse 
sequence contains user-specified delays between the 90
o
 and 180
o
 RF pulses for fat-
water-blood suppression.  The RF timing delays were leveraged to insert the preparatory 
stage required for the dreMR field shifting of B0, which under normal imaging situations 
would be held at the native field strength of the scanner.  In total, the dreMR pulse 
sequence contained the preparatory stage required for the dreMR field shifting (including 
TTL output signals for hardware synchronization) followed by an imaging stage for 
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acquisition.  The imaging sequence used was a Fast Spin Echo XL (FSE-XL).  The 
preparatory sequence is identical to what is played out in double/triple IR-prepared FSE 
scans for black blood imaging of the heart. The preparation stage included options such 
that the RF pulses could be suppressed when not required and the time duration of the 
field-shifting portion could be optimized.  The preparation stage was capable of including 
either one or two dreMR field shifts that could be separately specified for pulse duration 
and amplitude.  The dreMR pulse sequence is generalized in figure 2.2.  The simplest 
implementation of the dreMR pulse sequence included application of a 90
°
 RF pulse, 
followed by a single dreMR field shift (either negative or positive) and then standard 
image acquisition (designated: 90
°
-[Field Shift]-[Acquire]).  The single field shift encode 
also supported a 90
°
-180
°
-[Field Shift]-[Acquire] scheme.  A new double field shift 
encode, also known as the dreMR double inversion recovery (4), was developed using a 
90
°
-180
°
-[positive Field Shift]-180
°
-[negative Field Shift]-[Acquire] scheme, integrating 
both the positive and negative field shifts as part of the same preparation phase of the 
pulse sequence.  The first 90
°
 pulse in the preparatory stage is a hard pulse, whereas the 
180
°
 RF pulses are adiabatic. 
 
Figure 2.4 General dreMR pulse sequence diagram. LEFT: Single shift encode sequence.  
The    field shifts support both positive and negative field shifts.  RIGHT:  The double 
field shift encode sequence (DIR).   
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2.2.2 Preparatory pulse 
The preparatory stage of the dreMR sequence contains a number of necessary 
sequence parameters to completely specify either a single or double field shift encode.  
Different parameters are either activated or suppressed to achieve the desired preparatory 
sequence.  The sequence provides user control for the time durations between the 90
°
-
180
°
 RF pulses, the 180
°
-180
°
 RF pulses, the 90
°
 (or 180
°
) RF pulse to image acquisition, 
the time durations of the field shifts, and tunable delays between the RF pulses and field 
shifts.  The dreMR preparatory stage (Fig 2.5) is reduced to six important variables: the 
P1 time, the P2 time, the P3 time, the delay before the TTL turns on, and the positive and 
negative field shift durations.  These parameters correspond to the times indicated on 
figure 2.3.  The parameters are paramount to ensuring that not only does the preparatory 
stage provide the desired field shift, but that there are no timing overlaps between the 
preparatory stage and imaging stage.  For clarification, the P1 time is the time from the 
start of the first RF pulse to the middle of the second RF pulse, P2 time is the time from 
the middle of the second RF pulse to the middle of the third RF pulse, and the P3 time is 
the time from the middle of the third RF pulse to the start of normal FSE acquisition. 
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Figure 2.5 A detailed view of the preparation stage. P1, P2 and P3 times are graphically 
defined on the timeline. 
 
To achieve a single encode field shift dreMR pulse sequence, both the 180
°
 RF inversion 
pulses and P3 time are suppressed such that the preparatory stage only consists of the P1 
and P2 time durations with a positive or negative field shift (90
°
-[Field Shift]-[Acquire]).  
To achieve a double shift encode field shift dreMR pulse sequence, the entire preparatory 
sequence would be played out (Fig. 2.5). 
 
2.3 Analysis of dreMR Contrast 
Contrast derived from dreMR imaging, colloquially referred to as dreMR contrast, 
produces biophysical information not readily present with standard MRI techniques.  
dreMR imaging produces image contrast related to the magnetic field dependence of 
relaxation for a biological sample.  The contrast is obtained due to the relative lack of 
relaxation rate,   , field dependence from unenhanced tissues and tissues enhanced by 
non-targeted contrast agents (29, 32, 40, 48).  Taking advantage of the intrinsic lack of    
dispersion of the unenhanced tissues and non-targeted contrast agents, dreMR imaging 
produces contrast arising only from signal enhancement of tissues by only the bound form 
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of targeted contrast agents (4, 28, 49).  The relaxivity magnetic field dependence of the 
targeted form of contrast agent is measureable by manipulating the magnetic field 
strength of the MRI system during the preparatory stage of the pulse sequence prior to 
signal acquisition.  It is therefore the change in    with respect to the magnetic field 
strength,        , that is important for dreMR contrast  (Equations 2.1-2.4).  Given that  
 
                                    (2.1) 
 
the partial derivative of             with respect to the magnetic field,    is simply 
 
            
   
  
             
   
  
   
   
       (2.2) 
 
This relationship can be further simplified by the observation that  
             
   
                 )  (2.3) 
an approximation that is supported by literature (1, 8-10, 14, 29, 31, 48) and results 
acquired from field-cycling relaxometry data.  This results in a very simple relationship 
relating the change in    with respect to the magnetic field strength, contrast agent 
concentration and the magnetic field dependence of contrast agent relaxivity: 
 
            
   
  
   
   
       (2.4) 
 
There are two approaches to producing dreMR contrast.  The simplest method 
involves the weighted subtraction of two   -weighted images with different dreMR 
magnetic field shifts, one with a positive (   ) and the other with a negative (   ) 
magnetic field shift during the preparatory stage of the pulse sequence (27).  Subtraction 
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of the T1+ and T1- images would produce an image where the intensity would be due to the 
magnetic field dependence of the biological tissues and administered targeted contrast 
agent. 
A simplified derivation of the dreMR subtraction method is summarized below.  
The derivation assumes the pulse sequence starts with a saturation radiofrequency pulse 
to eliminate pre-existing longitudinal magnetization followed by a    preparatory pulse.  
The effect of finite ramping times for the    preparation pulse (i.e. effective offset field, 
∆Beff) is ignored since the ramping times (~ 1-2 ms) are significantly less than the 
duration of the pulse (~ 300 ms).  Application of the field-shifting pulse has two effects, it 
modulates the steady state longitudinal magnetization and it changes the relaxation rate, 
   of the sample.  The steady-state longitudinal magnetization is proportional to the 
amplitude of the sum of the field-shifting and clinical magnetic fields.  The application of 
a    preparation pulse scales    (the longitudinal magnetization at the clinical field 
strength) by a factor of           , effectively increasing the magnetization for a 
positive preparatory pulse and decreasing it for the negative preparatory pulse.  The 
longitudinal magnetization,    , available for imaging after a preparatory pulse     of 
duration,   , is therefore 
         
     
  
                     (2.5) 
where     is the relaxation rate for the sample at a magnetic field strength of      . 
The resulting image intensity of a positive or negative magnetic dreMR field shift 
is determined by extrinsic MR hardware, software and the readout sequence.  A scaling 
factor,  , can be included to account for the intrinsic and extrinsic factors (proton density, 
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radiofrequency coil homogeneity, transverse relaxation time, etc.), therefore the final 
image intensity would be the product of the scaling factor and   
                          (2.7) 
The dreMR subtraction methods takes the normalized difference of field-shifted images, 
   and   .  This normalization removes the influences of the changing equilibrium 
magnetization described above. 
         
  
     
    
  
     
   (2.8) 
                                                   (2.9) 
If the assumption is made that         is constant in the vicinity   , it is possible to 
approximate            for the resulting image intensity.  This assumption is only 
valid for specific contrast agents exhibiting a constant        within the imaging region 
of the dreMR magnetic field shifts (    . 
          , assuming a constant 
   
   
 (2.10) 
                                                          (2.11) 
                                                                   ]  (2.12) 
                                       (2.13) 
The equation quantifies the dreMR contrast intensity in a particular voxel after 
subtraction in terms of physical parameters such as   ,   , and the change in   .  The 
hyperbolic sine term accounts for the characteristic contrast produced by the dreMR 
method.  The exponential decay function accounts for the inherent loss of contrast that 
occurs when the longitudinal relaxation time is set too long such that the voxel 
magnetizations of the images begin to saturate. 
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The second method involves a single T1-weighted sequence referred to as Double 
Inversion Recovery (DIR) dreMR pulse sequence (dreMR-DIR) (see Fig. 2.2).  Similar to 
conventional inversion recovery sequences, where signal intensities from tissue with 
specific relaxation rates are suppressed based on inversion times, the dreMR-DIR pulse 
sequence suppresses signals arising from tissues without a relaxation rate magnetic field 
dependence,         (4).  During the preparatory stage of the pulse sequence, two field-
shifting pulses and two RF 180
°
 inversion pulses are applied to maximize the image 
contrast for dependence of         and minimize it for dependence of    at the end of 
the preparatory stage of the pulse sequence (start of the imaging sequence).  The dreMR-
DIR sequence therefore directly measures the relaxation rate magnetic field dependence 
and does not required any image post processing. 
 
2.4 Phantom Preparation 
MRI phantoms (Fig. 2.6) were prepared for analysis using the dreMR pulse 
sequences.  The samples contained various concentrations of Ablavar and rabbit serum 
albumin and were all dissolved in 1× phosphate buffer saline (PBS), pH of 7.4 (KH2PO4 
1.06 mM, NaCl 155.17 mM, Na2HPO4-7H2O 2.97 mM) (Product Code 10010023, Gibco, 
Invitrogen, Burlington, ON, Canada).  The rabbit serum albumin (RSA) was purchased as 
a lyophilized powder, essentially globulin free (~99 %) (Sigma-Aldrich, lot 
#117K7565V, agarose gel electrophoresis). 
The phantom (Fig. 2.6) was prepared in a grid-like fashion with various sample 
concentrations of RSA and Ablavar.  Samples from left to right contained increasing 
concentrations of RSA dissolved in PBS: 0 μM, 50 μM, 100 μM, 350 μM, and 700 μM.  
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Samples from top to bottom contained increasing concentrations of Ablavar dissolved in 
PBS: 0 μM, 50 μM, 100 μM, 250 μM, 500 μM, and 1000 μM. 
 
Figure 2.6 The arrangement of samples in the phantom.  Samples from left to right 
contained increasing concentrations of RSA, ranging from 0 to 700 μM.  Samples from 
top to bottom contained increasing concentrations of Ablavar, ranging from 0 to 1000 
μM. 
 
2.5 Field-Cycling Relaxometry 
 
Figure 2.7 Basic Nonpolarized and Prepolarized sequence.  The upper trace shows the 
switching of field values between the fixed polarization field (  ), the variable relaxation 
field (  ), and the fixed detection field (  ), whereas the bottom trace shows the RF 
pulse followed after a small delay by the FID acquisition. 
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DreMR contrast is derived from the relaxivity magnetic field dependence of the 
bound targeted MR contrast agent.  The characteristic high relaxivity magnetic field 
dependence of bound paramagnetic contrast agents enables suppression of tissue contrast 
from unbound agents and unenhanced tissue, thereby increasing probe specificity. 
Ablavar binds specifically to serum albumin and has a strong magnetic field dependence 
for serum albumin around 1.5T (1, 8, 19).  A sample of 80-μM Albavar dissolved in 4% 
w/v RSA was measured and acquired using nuclear magnetic resonance dispersion 
(NMRD) data for magnetic field strengths ranging from 0.010 MHz (0.23 mT) to 42.49 
MHz (1.0 T), using a SpinMaster FFC2000 1T C/DC (Stelar s.r.l., Italy) fast field-cycling 
nuclear magnetic resonance relaxometer.  Typical methods to measure T1-dispersion 
profiles (plots of longitudinal relaxation times as a function of field intensity at a constant 
temperature) at variable field strengths below 1 T are the prepolarized sequence (PP), 
appropriate for low relaxation fields (Br), and the nonpolarized sequence (NP), 
appropriate at higher relaxation fields (Fig. 2.5).  The pulse sequence comprised of the 
NP and PP sequences with a crossover field of 12 MHz (i.e. the relaxation field at which 
the sequence switches from NP to PP).  The sequences were automated experiments 
designed to measure the longitudinal relaxation rate (R1) at a given relaxation field.  For 
every given   , the FID signal was measured as a function of the time interval tau (τ) 
(variable relaxation interval), keeping the other (switching, recycle delay, polarization, 
acquisition) times constant.  The NP and PP were comprised of the same systematic 
setup, the only difference was that the NP sequence had a polarization field set to zero (Bp 
= 0).  Each sequence block FID acquisition started with a recycle delay set to ten times 
the maximum T1 (         , followed by a balancing time of         –  , to balance 
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thermal dissipation in the magnet.  The relaxometer cycled to the polarization field of 30 
MHz for a time of          to reach a steady state of magnetization, then cycled to the 
relaxation field (  ) for an interval time of τ.  The relaxometer finally cycled to the 
acquisition field of 16.2 MHz, after which a 90
°
 RF pulse was applied and the FID signal 
was acquired.  The sequence was repeated for 16 blocks, with a decreasing relaxation 
interval (τ), to calculate the relaxation time at the specific relaxation field with an 
automated multiblock non-linear, least squares fit.  The process was repeated for 30 
points (determined by the relaxometer on a logarithmic scale) to complete the T1-
dispersion profile.   
At higher field strengths, an insertable field-cycling relaxometer system (MRIn, 
Stelar s.r.l., Italy) was used to acquire NMRD curves for ± 0.25 T field shifts about the 
clinical field strengths of 1.5 T.  An Inversion Recovery sequence was used, similar to the 
PP sequence, except the relaxometer cycled to the acquisition field after the polarization 
field and applied a 180 RF pulse before cycling to the relaxation field.  The polarization 
and acquisition fields of the insertable field-cycling relaxometer were set to zero 
corresponding to a Larmor frequency of 63.86 MHz at 1.5T.  
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Figure 2.8 NMRD data was acquired using the Spinmaster FFC2000 1T C/DC (Stelar 
s.r.l., Italy)  and MRIn equipment.  NMRD data for magnetic field strengths ranging from 
0.010 MHz to 42.49 MHz was acquired using the SpinMaster relaxometer (Top Left).  
Top Right and Bottom Row: The insertable field-cycling relaxometer system (MRIn, 
Stelar s.r.l., Italy) used to acquire NMRD curves for ± 0.25 T field shifts about the 
clinical field strengths of 1.5 T (Top Right and Bottom Row). 
 
The relaxation rates for the contrast agent solution of 80 μM Albavar dissolved in 
4% w/v RSA was measured and acquired (        ) and the plain buffer solvent 
(         ) were recorded for computing the relaxivity (  ) of the contrast agent,  
                          (2.14) 
where [CA] represents the concentration of the contrast agent sample on a per gadolinium 
ion basis.  The estimated R1 error interval was 2% or less.  Samples were maintained at 
37  for all measurements using heated air.   
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Longitudinal relaxation was modeled using a modification of the Solomon-
Bloembergen-Morgan theory formulated by R. Lauffer (9).  Contributions to spin-lattice 
relaxation from the inner hydration sphere were calculated as: 
 
 
  
 
  
 
   
     
   
      
  (2.15) 
where           was the spin-lattice relaxation rate due to inner-sphere interactions, [M] 
was the molar concentration of the paramagnetic species, [H2O] was the molar 
concentration of water, qIS was the inner-sphere hydration number, T1M was the relaxation 
time for bound inner-sphere water molecules, and τm was the water residency time. 
The inner sphere spin-lattice relaxation rate, including dipolar and contact 
interactions, was estimated using: 
 
   
  
 
  
  
  
  
 
   
   
         
 
    
  
   
    
    
 
   
    
    
  
 
 
 
       
 
 
 
 
 
  
    
   
   (2.15) 
where    was the magnetic permeability of vacuum,    was the gyromagnetic ratio for 
protons,    was the electronic g-factor,    was the total electronic spin for the metal 
ion,    was the Bohr Magneton,      was the metal ion-proton separation and 
 
 
 was the 
electron-nuclear hyperfine coupling constant.     and    were the proton and electron 
Larmor precessional frequencies (rad/s) in the applied magnetic field respectively. 
The dipole-dipole correlation time,   , was calculated from the longitudinal 
electronic spin relaxation time,    , the water residency time,    and the rotational 
correlation time,   , as follows:  
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The longitudinal electronic spin relaxation rate is parameterized as:  
 
   
   
 
    
   
   where   
 
    
 .  (2.17) 
Finally, the scalar relaxation time,   , was determined by: 
 
  
 
 
   
 
 
  
.  (2.18) 
2.6 Animal Preparation 
The animal experiments were approved by the Animal Use Subcommittee of the 
University Council on Animal Care at The University of Western Ontario following the 
guidelines of the Canadian Council on Animal Care (protocol number 2010-210 and 
2011-085) (Appendix B and C). 
A total of three mice were used, all following the same preparation, anesthesia, 
and injection protocols for imaging.  Two cancer model mice were used for the dreMR 
subtraction method, and one healthy mouse was used for the dreMR-DIR method.   
 The mice were initially anesthetized with 5% Isoflurane (Baxter Corporation, 
Mississauga, ON, Canada) with a vaporizer (VetEquip, Pleasanton, CA, USA) in an 
induction chamber.  The mice were fitted with a breathing rate monitor (Small Animal 
Instruments Inc., Stony Brook, NY, USA) to monitor the breathing rates under anesthesia 
and then transferred to a custom water-heated mouse bed where Isoflurane was 
administered (reduced to 2% with O2) through a nose cone.  The Isoflurane concentration 
was adjusted between 1-3% during the imaging session based on breathing rate.  The 
water temperature of the mouse bed was controlled to body temperature with a T/Pump 
(Gaymar, Torrington, CT, USA).  The mice were injected by tail-vein with a bolus of 
Ablavar diluted in saline at a dose of 100 μM/kg.  The two cancer model mice were 
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sacrificed using Euthanyl Forte (Pentobarbital Sodium Injection) at a dose of 2 mL/kg 
(Bimeda-MTC Animal Health Inc, Cambridge, ON, Canada). 
 
2.6.1 Prostate Cancer model  
PC-3M cells (NCI, Frederick, MD, USA) were cultured in RPMI-1640 
supplemented with 10% fetal bovine serum (FBS) (Gibco, Invitrogen, Burlington, ON, 
Canada).  All cells were maintained at 37   and 5% CO.  Two million PC-3M cells 
suspended in 100 μL Hank's Balanced Salt Solution (HBSS) (Gibco, Invitrogen, 
Burlington, ON, Canada) were injected subcutaneously in the right and left ﬂanks of a 
female (19 g) nude mouse (nu/nu; Charles River Laboratories, QC, Canada) at day 0 (50).  
The mouse was imaged on day 28. 
 
2.6.2 Breast Cancer model 
MDA-MB-231 cells (ATCC, Manassas, VA, USA) were cultured in Dulbecco's 
modiﬁed Eagle's medium (DMEM) supplemented with 10% FBS.  All cells were 
maintained at 37   and 5% CO.  One million MDA-MB-231 cells suspended in 50-μL 
HBSS were injected into the mammary fat pad on the left side of a female (18 g) nude 
mouse (nu/nu; Charles River Laboratories, QC, Canada) at day 0.  The mouse was 
imaged on day 29. 
 
2.7 Magnetic Resonance Acquisition and Image Processing 
The dreMR pulse sequence was a custom-built sequence based on a standard 
imaging sequence known as the Triple Inversion Recovery.  The pulse sequence consisted 
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of a preparatory stage, whereby the    magnetic field shifts were applied, followed by 
imaging acquisition.  The    magnetic field shifts were applied for each row of k-space 
and were timed to end 2 ms prior to image acquisition.  The dreMR subtraction method 
takes the normalized difference of the field-shifted images: positive field shifted images 
(   , and negative field shifted images (   .  The raw data for all images were acquired to 
perform the image processing.  The data sets were first normalized (to remove the 
influences of the changing equilibrium magnetization) and scaled (if there were multiple 
images were taken).  A subtraction-based pixel by pixel phase correction was then applied 
to minimize the effects phase shifts induced by the eddy currents.  The phase difference 
of the k-space data from the    and    data sets was calculated and applied to one of the 
data sets (either    or   ).  A complex subtraction of the    and    data sets calculated 
before obtaining the final magnitude dreMR image.  The double inversion recovery 
dreMR sequence required no image processing.  All the image processing was performed 
using Matlab 2012 tools (MathWorks, Natick, Massachusetts, U.S.A.) 
 
2.8 Magnetic Resonance Imaging 
2.8.1 Phantoms 
The fast spin-echo pulse sequence parameters used to produce the dreMR images 
using the dreMR subtraction method were: 1000-ms pulse repetition time, 12.08-ms echo 
time, echo train length of two, 122 Hz per pixel, one average, isotropic in-plane resolution 
of 0.27 mm, and 15-mm slice thickness.  The matrix size was 256256..  The main 
magnetic field was modulated ±0.221 T with preparatory dreMR pulse of 500-ms 
duration.  The ΔB pulses were timed to end 2 ms prior to image acquisition. 
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The dreMR-DIR (Double Inversion Recovery) sequence parameters used to 
produce the dreMR images using the dreMR DIR method were: : 450-ms pulse repetition 
time, 6.904-ms echo time, 50-ms inversion time, echo train length of two, 122 Hz per 
pixel, one average, isotropic in-plane resolution of 0.55 mm, and 8-mm slice thickness.  
The matrix size was 128128.  The main magnetic field was modulated with preparatory 
dreMR pulse durations of a 50-ms P1 time, a P2 time of 150 ms with a positive 0.221-T 
magnetic field shift, and a P3 time of 50 ms with a negative 0.221-T magnetic field shift.  
The ΔB pulses were timed to end 2 ms prior to image acquisition. 
 
2.8.2 In vivo Research 
2.8.2.1 Prostate Cancer Model 
The fast spin-echo pulse sequence parameters used to produce the axial dreMR 
images using the dreMR subtraction method were: 500-ms pulse repetition time, 9.376-
ms echo time, echo train length of two, 81 Hz per pixel, one average, isotropic in-plane 
resolution of 0.39 mm, and 4-mm slice thickness.  The matrix size was 128128.  The 
main magnetic field was modulated ±0.221 T with preparatory dreMR pulses of 300-ms 
duration.  The ΔB pulses were timed to end 2 ms prior to image acquisition.  Nine data 
sets were averaged to produce the resulting dreMR image.  Two 4-mm-diameter NMR 
vials containing 160 μM of Ablavar loaded with and without 4.0% w/v RSA were placed 
within the imaging region of the tumours to serve as dreMR contrast controls.    - and   -
weighted were also obtained before and after Ablavar was injected into the animal.   
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2.8.2.2 Breast Cancer Model 
The fast spin-echo pulse sequence parameters used to produce the axial dreMR 
images using the dreMR subtraction method were: 500-ms pulse repetition time, 9.376-
ms echo time, echo train length of two, 81 Hz per pixel, one average, isotropic in-plane 
resolution of 0.39 mm, and 4-mm slice thickness.  The matrix size was 128128  Ten data 
sets were averaged to produce the resulting dreMR image.  The fast spin-echo pulse 
sequence parameters used to produce the coronal dreMR images using the dreMR 
subtraction method were: 500-ms pulse repetition time, 8.512-ms echo time, echo train 
length of two, 81 Hz per pixel, 10 averages, in-plane resolution of 0.93x0.38 mm, and 4-
mm slice thickness.  The main magnetic field was modulated ±0.221 T with preparatory 
dreMR pulses of 300 ms in duration.  The ΔB pulses were timed to end 2 ms prior to 
image acquisition. Two 4-mm-diameter NMR vials containing 160 μM of Ablavar loaded 
with (labeled 2) and without (labeled 1) 4.0% w/v RSA were placed within the imaging 
region of the tumours to serve as dreMR contrast controls.    - and   -weighted were also 
obtained before and after Ablavar was injected into the animal.   
 
2.8.2.3 Healthy Mouse – DIR sequence 
The dreMR-DIR (Double Inversion Recovery) sequence parameters used to 
produce the dreMR images using the dreMR DIR method were: 450-ms pulse repetition 
time, 6.744-ms echo time, 50-ms inversion time, echo train length of two, 122 Hz per 
pixel, five averages, isotropic in-plane resolution of 0.70 mm, and 2-mm slice thickness.  
The matrix size was 128128.  The main magnetic field was modulated with preparatory 
dreMR pulse durations of a 100-ms P1 time, a P2 time of 100 ms with a positive 0.221-T 
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magnetic field shift, and a P3 time of 90 ms with a negative 0.221-T magnetic field shift.  
The ΔB pulses were timed to end 2 ms prior to image acquisition.  Two 4-mm-diameter 
NMR vials containing 160 μM of Ablavar loaded with (2) and without (1) 4.0% w/v RSA 
were placed within the imaging region of the tumours to serve as dreMR contrast 
controls.    -weighted images were obtained, prior to Ablavar injection, to overlay the 
dreMR-DIR image. 
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Chapter 3  
Results 
In Chapter 3, the relaxation rates of 80-μM Albavar dissolved in 4% w/v RSA 
were measured for magnetic field strengths ranging from 0.010 MHz (0.23 mT) to 42.49 
MHz (1.0 T), and an insertable field-cycling relaxometer system was used to acquire 
NMRD curves for ± 0.25 T field shifts about the clinical field strengths of 1.5 T.  The 
relaxometry data analysis demonstrated the basis by which the dreMR contrast is derived 
during MR imaging.  dreMR imaging was performed using the single inversion 
subtraction method and the double inversion recovery method.  Phantoms and in vivo 
mouse models were used for both dreMR imaging methods, and the resulting dreMR 
contrast images are shown.  The appropriate image post-processing are implanted to 
correct for the necessary field normalization and phase corrections for the single inversion 
subtraction based method. 
3.1 Relaxometry Data - Fitting Results Using Lauffer Model of 
Relaxivity 
    dispersion experiments were conducted to measure the field dependence of 
NMR spin-lattice relaxation times of 80-μM Ablavar with and without RSA from 10 kHz 
to 64 MHz (NMRD profiles) using the SpinMaster FFC2000 1T C/DC and MRIn 
relaxometers.  The red line (Fig. 3.1 A and B) indicates the imaging region of interest.  
dreMR is able to exploit the characteristic high relaxivity magnetic field dependence of 
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the bound paramagnetic contrast agent about 1.5 T (63.86 MHz) to produce image 
contrast that is proportional to the concentration of the targeted contrast agent.  The 
significant change in relaxivity between the bound (Fig. 3.1 A) and unbound (Fig. 3.1 B) 
contrast agent is noted in the change in scale of the two graphs below. 
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Figure 3.1 Fitting Results Using Lauffer Model of Relaxivity for 80-μM sample of 
Ablavar measured at 37°C. The Lauffer model for inner-sphere dipole-dipole relaxation 
(red trace) has been fit to relaxivities derived from NMRD data at 37°C.  (circles) Sample 
with 4% w/v Rabbit Serum Albumin. (triangles) No Rabbit Serum Albumin. 
 
Table of Fitting Results 
Table 1. Longitudinal relaxation model using a modification of the Solomon-
Bloembergen-Morgan theory formulated by R. Lauffer.  The fitted parameters and their 
uncertainties (one standard deviation) are given in the following table. 
  Ablavar with RSA Ablavar 
Parameter Units 37°C 37°C 
   ps 38.4 ± 4.2 102.0 ± 14 
   ns 5.72 ± 0.59 0.24 ± 0.01 
   ns 552 ± 19 552 (fixed) 
    ps 578 ± 50 154.3 ± 5.9 
    rad/s 3*106 (fixed) 3*106 (fixed) 
     pm 0.31 (fixed) 0.31 (fixed) 
    - 1 (fixed) 1 (fixed) 
  : Correlation time for modulation of the transient zero-field splitting,   : Rotational correlation 
time,   : Water residency time,    : Electronic relaxation time at zero field,    : electron-
nuclear hyperfine coupling constant,     : metal ion-proton separation,      inner-sphere 
hydration number  
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3.2 Phantom Images 
3.2.1 dreMR Single Inversion subtraction 
A phantom study was conducted in which the dreMR single inversion subtraction 
method was implemented to produce a dreMR image.  The method required the weighted 
subtraction of two   -weighted images with ±0.221 T dreMR magnetic field shifts, one 
with a positive (   ) and the other with a negative (   ) magnetic field shift during the 
preparatory stage of the pulse sequence.  Subtraction of the T1+ and T1- images produce an 
image where the contrast intensity was due to the magnetic field dependence of the 
targeted contrast agent.  Phantoms (Fig. 3.2) were prepared in a grid-like fashion with 
various sample concentrations of RSA and Ablavar in order to test the proposed method 
without any physiological effects.  The resulting dreMR image is presented as a false-
colour image. 
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Figure 3.2 Phantom and MRI images.  Top: Arrangement of the samples in the phantom. 
Samples from left to right contained increasing concentrations of RSA, ranging from 0 to 
700 μM.  Samples from top to bottom contained increasing concentrations of Ablavar, 
ranging from 0 to 1000 μM.  Bottom: Subtraction of the   -weighted images.  Images A 
and B show the   -weighted images using the dreMR pulse sequence with positive (A) 
and negative (B) field shifts of 0.221 T.  Image C shows the resulting dreMR image using 
the dreMR subtraction method. 
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3.2.2 dreMR Double Inversion Recovery 
A phantom study was conducted in which the dreMR Double Inversion Recovery 
method was implemented to produce a dreMR image.  Similar to conventional inversion 
recovery sequences, where signal intensities from tissue with specific relaxation rates are 
suppressed based on inversion times, the dreMR-DIR pulse sequence suppresses signals 
arising from tissues without a relaxation rate magnetic field dependence and therefore 
required no image processing.  Phantoms (Fig. 3.3 A) were prepared in a grid-like fashion 
with various sample concentrations of RSA and Ablavar in order to test the proposed 
method without any physiological effects.  A   -weighted image (Fig. 3.3 B) was 
acquired using a standard fast spin-echo pulse sequence to observe and measure the 
resulting contrast from the dreMR-DIR image (Fig. 3.3 C).  The dreMR-DIR image is 
presented as a grayscale image to compare with the standard FGRE sequence. The 
samples with the lowest concentrations of Ablavar and RSA exhibit limited signal 
intensities, while the samples with the larger concentrations of Ablavar and RSA show 
increased signal intensities. 
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Figure 3.3 Phantom and MRI images.  Top: (A) Arrangement of the samples in the 
phantom. Samples from bottom to top contained increasing concentrations of RSA, 
ranging from 0 to 700 μM.  Samples from left to right contained increasing concentrations 
of Ablavar, ranging from 0 to 1000 μM.  (B)   -weighted image using a standard fast 
gradient echo pulse sequence acquired at 1.5 T (no field shifting).  (C)  Image shows the 
resulting dreMR image acquired with the dreMR-DIR sequence.  The dreMR-DIR 
method demonstrates the ability to both suppress and enhance signal intensities of various 
albumin concentrations bound to various Ablavar concentrations without any post 
processing. 
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3.3 In vivo Images 
3.3.1 Prostate Cancer Model 
An in vivo study was conducted in which the dreMR single inversion subtraction 
method was implemented to produce a dreMR image.  The method required the weighted 
subtraction of two   -weighted images with ±0.221 T dreMR magnetic field shifts, one 
with a positive (   ) and the other with a negative (   ) magnetic field shift during the 
preparatory stage of the pulse sequence.  Subtraction of the T1+ and T1- images produce an 
image where the contrast intensity was due to the magnetic field dependence of the 
targeted contrast agent.  A female NU/NU mouse was injected with the human prostate 
cancer cell line PC-3M and developed tumours on both flanks  The mouse was imaged 28 
days post PC-3M cell injections. Two 4-mm NMR vials containing 160 μM of Ablavar 
loaded with and without 4.0%w/v RSA were placed within the imaging region of the 
tumours to serve as dreMR contrast controls.  Axial   -weighted images pre- (Fig. 3.4 A) 
and post-injection (Fig. 3.4 B) of albumin-targeted gadolinium contrast agent (Ablavar), 
and axial   -weighted image (Fig. 3.4 C) post-injection were taken and indicated a 
significant tumour volume.  Axial   -weighted subtracted images of post- and pre-
injection of Ablavar (false colour (3.4 D) and grayscale (3.4 E)) were taken to indicate 
regions where gadolinium was present.  Subtraction of the T1+ and T1- images produced a 
dreMR image (Fig. 3.4 F).  Taking advantage of the intrinsic    dispersion of the 
unenhanced tissues and non-targeted contrast agents, the dreMR single inversion 
subtraction method produced contrast arising only from signal enhancement of tissues by 
only the bound form of targeted contrast agent.  The resulting dreMR image is presented 
as a false-colour image.  
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Figure 3.4 Axial image of a female NU/NU mouse under study that developed prostate 
cancer tumours on both flanks and imaged 28 days post PC-3M cell injections. Two  
4-mm NMR vials containing 160 μM of Ablavar loaded (2) with and (1) without 4.0% 
w/v RSA were placed within the imaging region of the tumours to serve as dreMR 
contrast controls.  Top: (A and B)   -weighted images pre- and post-injection of Ablavar. 
(C)   -weighted image indicating significant tumour volume.  The tumours are 
demarcated and indicated with the arrows.  Bottom (D and E).    -weighted subtracted 
images of post- and pre-injection of Ablavar ((D) and (E)) indicate regions where 
gadolinium was present.  (F) Resulting dreMR axial image using the dreMR subtraction 
method.  Notice the dramatic change in contrast from the standard pre- and post-injection 
subtracted images compared to the dreMR image.  The contrast from the dreMR image 
shows only signal intensities arising from the bound form of Ablavar and albumin. 
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3.3.2 Breast Cancer Model 
An in vivo study was conducted in which the dreMR single inversion subtraction 
method was implemented to produce a dreMR image.  The method required the weighted 
subtraction of two   -weighted images with ±0.221 T dreMR magnetic field shifts, one 
with a positive (   ) and the other with a negative (   ) magnetic field shift during the 
preparatory stage of the pulse sequence.  Subtraction of the T1+ and T1- images produce an 
image where the contrast intensity was due to the magnetic field dependence of the 
targeted contrast agent.  A female NU/NU mouse was injected with the human breast 
cancer cell line MDA-MB-231 and developed a tumour in the mammary fat pad on the 
left side.  The mouse was imaged 29 days post MDA-MB-231 cell injections.  Two 4-mm 
NMR vials containing 160 μM of Ablavar loaded with and without 4.0% w/v RSA were 
placed within the imaging region of the tumours to serve as dreMR contrast controls. 
Axial   -weighted images pre- (Fig. 3.5 A) and post-injection (Fig. 3.5 B) and coronal 
(Fig. 3.5 F) of albumin-targeted gadolinium contrast agent (Ablavar), and axial   -
weighted image (Fig. 3.5 C) post-injection were taken and indicated significant a tumour 
volume.  Subtraction of the T1+ and T1- images pre- (Fig. 3.5 D) and post-injection (Fig. 
3.5 E and 3.5 F) of Ablavar produced an axial and coronal dreMR images.  Taking 
advantage of the intrinsic    dispersion of the unenhanced tissues and non-targeted 
contrast agents, the dreMR single inversion subtraction method produced contrast arising 
only from signal enhancement of tissues by only the bound form of targeted contrast 
agent.  The resulting dreMR images are presented as a false-colour image. 
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Figure 3.5 Axial and coronal images of a female NU/NU mouse under study that 
developed a large breast cancer tumour in the mammary fat pad and imaged 29 days post 
MDA-MB-231 cell injections. Two 4-mm NMR vials containing 160 μM of Ablavar 
loaded (2) with and (1) without 4.0% w/v RSA were placed within the imaging region of 
the tumours to serve as dreMR contrast controls.  Top: (A and B)   -weighted images 
pre- and post-injection of albumin-targeted gadolinium contrast agent (Ablavar). (C)   -
weighted image indicating significant tumour volume.  The tumours are demarcated and 
indicated with the arrows.  Bottom (D and E).  Resulting dreMR axial image using the 
dreMR subtraction method of (D) pre- and (E) post-injection of Ablavar.  (F)   -weighted 
post-injection coronal images with the tumour demarcated.  (G) Resulting dreMR coronal 
image using the dreMR subtraction method post-injection of Ablavar.  The significant 
change in contrast from the dreMR image shows only signal intensities arising from the 
bound form of Ablavar and albumin. 
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3.3.3 Double Inversion Recovery 
An in vivo study was conducted in which the dreMR Double Inversion Recovery 
method was implemented to produce a dreMR image.  Similar to conventional inversion 
recovery sequences, where signal intensities from tissue with specific relaxation rates are 
suppressed based on inversion times, the dreMR-DIR pulse sequence suppresses signals 
arising from tissues without a relaxation rate magnetic field dependence and therefore 
required no image processing.  Two 4-mm NMR vials containing 160 μM of Ablavar 
loaded with and without 4.0% w/v RSA were placed within the imaging region of the 
tumours to serve as dreMR contrast controls.  A standard   -weighted image (Fig. 3.6 A) 
image using a standard fast gradient echo pulse sequence acquired at 1.5 T (no field 
shifting) was taken to overlay the dreMR-DIR image (Fig. 3.6 B).  The dreMR-DIR 
image was acquired with the magnetic field shifting parameters of 100-ms positive 0.221-
T magnetic field shift (P2 Time) and 90-ms negative 0.221 T magnetic field shift observe 
and measure the resulting dreMR-DIR image (Fig. 3.6 B).  The dreMR-DIR image is 
presented as a false-colour image overlaid with the standard FGRE   -weighted image 
(Fig. 3.6 C). 
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Figure 3.6 Direct albumin imaging using the dreMR Double Inversion Recovery (DIR) 
pulse sequence.  Two 4-mm NMR vials containing 160 μM of Ablavar loaded with and 
without 4.0% w/v RSA were placed within the imaging region to serve as dreMR contrast 
controls.  Top left (A):   -weighted image using a standard fast gradient echo pulse 
sequence acquired at 1.5 T.  Bottom left (B): dreMR-DIR image with 100-ms positive 
0.221 T magnetic field shift (P2 Time) and 90-ms negative 0.221 T magnetic field shift.  
Right (C): Overlay of dreMR-DIR and   -weighted image.  The dreMR-DIR method 
enables suppression of unbound agents and unenhanced tissues contrast, thereby 
increasing agent specificity. 
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Chapter 4  
Discussion 
 
4.1 Discussion 
Delta Relaxation Enhanced magnetic resonance (dreMR) is an imaging method 
capable of producing contrast proportional only to the concentration of the bound form of 
the targetable contrast agent using a dynamic field-cycling technique.  The characteristic 
high relaxivity magnetic field dependence of bound paramagnetic contrast agents enables 
suppression of unbound agents and unenhanced tissues contrast.  The ability to adapt 
field-cycling relaxometry to MRI increases its sensitivity to image contrast agents with 
molecular targeting characteristics.  The effect of removing the magnetic field shifting 
pulses during the preparatory phase of the pulse sequence diminishes the ability to 
distinguish dreMR contrast arising due to the targeted form of the targetable contrast 
agent.  Without the magnetic field shifts, the relaxivity magnetization field dependence 
cannot be exploited and the contrast would produce a conventional T1-weighted image.  
The dreMR single inversion subtraction and double inversion recovery methods both 
exploit the relaxivity magnetic field dependence, albeit in different ways.   
Using field-cycling relaxometry, it can be seen the relaxation field dependence, 
   
   
, presents strong evidence of contrast agent binding (Fig. 3.1 A and B), evident by the 
relaxivity dispersion.  At 1.5 T, the relaxivity of the targeted and non-targeted contrast 
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agent with rabbit serum albumin was 16 mM
-1
s
-1
 and 7.5 mM
-1
s
-1
, which was in 
agreement with values reported in literature (1, 12, 19).   
The significance is not the relaxivity at a fixed magnetic field strength, but rather 
its change with respect to the magnetic field.  From the relaxometry data, imaging with 
the administration of Ablavar at 1.5 T would result in an absolute relaxivity enhancement 
of 2.1 (ratio of targeted Ablavar to non-targeted Ablavar), whereas the relaxivity slope 
enhancement ratio was 95 (from 1.25 T to 1.75 T).  The large increase of the relaxivity 
slope enhancement ratio over the absolute relaxivity enhancement of only the targeted 
form of Ablavar (non-enhanced tissues and non-targeted Ablavar do not demonstrate 
strong relaxivity field dependences (9, 29)) is what makes dreMR imaging feasible.  The 
phantom experiments demonstrate magnetization can be prepared and produce signal 
intensities proportional to 
   
   
 using both dreMR imaging techniques (single inversion and 
double inversion). 
The single inversion subtraction dreMR technique required an acquisition of two 
images acquired with magnetic field shifts, equal in duration and magnitude.  The raw 
data from the field-shifted images are then normalized to remove the influences of the 
changing equilibrium magnetization through post-processing.  Minor inductive coupling 
between the dreMR B0 insert coil and the clinical MRI system produce eddy currents in 
the conductive materials in the MRI system, even with the use of active shielding.  The 
eddy currents create a frequency offset such that there became a shift within the field-of-
view along the frequency encoding and slice selection directions.  The phase-based 
correction was meant to correct only the shift in the frequency encoding direction.  Eddy 
currents induced by the rapid switching dreMR B0 insert coil reduces the quality of the 
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final dreMR image, therefore a phase-based correction was applied to the positive and 
negative   -weighted images.    The phase difference from the k-space data from the 
positive and negative field variations were minimized to correct for this observation.  
After the appropriate field normalizations and phase correction, a complex subtraction of 
the complex k-space data was performed before obtaining the final magnitude dreMR 
image.  The final dreMR images (refer to Figures. 3.4 F and 3.5 E and G) produced by the 
subtraction based single inversion dreMR technique produces contrast proportional to 
   
   
, 
where the magnetic field shifts were created by the dreMR B0 field-cycling insert coil.  
The penalty for the single inversion subtraction dreMR technique is a drop-off in SNR, a 
reduction of approximately 20%, however the gains in probe specificity more than 
compensate for this drawback.   
Prior to injection of Ablavar, the dreMR image (Fig 3.5 D) produced no tissue 
contrast.  Post-injection of Ablavar (Fig 3.4 B, Fig. 3.5 B), the T1-weighted images 
showed an increase in contrast associated with accumulation of Ablavar, however the 
ability to distinguish contrast arising from the only the targeted form of Ablavar became 
difficult since contrast from unenhanced tissues and non-targeted Ablavar were still 
present.  A post- minus pre-Ablavar injection (Fig. 3.4 D) nicely defined regions where 
the contrast agent was present; however it was only the final dreMR image that showed 
regions where Ablavar was targeted to albumin.  The in vivo dreMR images showed an 
increase in contrast around the periphery of the tumours (Fig. 3.4 F, Fig. 3.5 E and G).  
The presence of the two phantoms placed beside the mouse during imaging served as 
dreMR contrast controls and showed the contrast from the dreMR images were due to 
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only the targeted form of Ablavar.  Without histological examination, characterizations 
about the tumour and surrounding vascular environment were not feasible. 
 The double inversion recovery (DIR) dreMR sequence differs from the single 
inversion subtraction dreMR technique such that the DIR method can directly prepare 
magnetization based upon 
   
   
 without any image post-processing.  During the preparatory 
section of the dreMR-DIR pulse sequence, two    (±0.221 T) field-shifting pulses and 
two 180
°
 RF pulses are applied prior to the start of the image acquisition sequence.  The 
DIR preparatory pulse sequence was similar to standard inversion recovery pulse 
sequences that were meant to minimize sample magnetization from fat and water (51).  
The DIR preparatory pulse sequence was applied to maximize the magnetization 
dependence of  
   
   
 and minimize the magnetization dependence of    before the start of 
image acquisition (4).  The three periods within the preparatory phase (P1 time, P2 time, 
and P3 time) were optimized for magnetization evolution producing contrast only from 
   
   
 of the targeted form of the Ablavar, and to suppress any contrast resulting from 
sample tissues and the non-targeted form of Ablavar (4).  The 
   
   
 dependence was a 
strong indication of Ablavar-albumin binding and the dreMR-DIR image presented 
contrast the localized targeted binding.  The resulting image intensity depended on factors 
including the concentration of albumin and Ablavar, proton density and magnitude of the 
dreMR magnetic field shift.  The dreMR-DIR image of a healthy mouse presented in 
figure 3.6 B and C, showed dreMR contrast in the kidneys and bladder due to the time 
differences between the injection of Ablavar and the image acquisition (40 minutes) and 
fast clearance of the contrast agent. 
72 
 
4.2 Limitations and Future Work 
We identified a number of limitations within the scope of the initial in vivo dreMR 
imaging analysis and results that motivate the future direction of dreMR imaging.  Areas 
of interest include: Ablavar bio-distribution and quantification, histological and 
immunohistochemical characterization of the tumour vascular environment, and 
improving the dreMR imaging technique. 
4.2.1 Ablavar Binding and Relaxivity 
The development of Ablavar towards FDA-approval for use as an MRI 
intravascular contrast agent has been focused and optimized for use in humans (12, 19, 
52), and as such, the albumin binding affinities and relaxivities exhibit a species 
dependence.  Ablavar was designed to bind strongly and reversibly with human serum 
albumin in plasma, allowing for long vascular retention and plasma half-life (52), and an 
relaxivity increase 6-10 times that of Gd-DTPA (19, 52).  However, because the albumin 
binding is reversible, the relaxivity will depend on dose and time of injection, and species 
binding affinities.  Not only does the total volume fraction albumin vary among species, 
but the binding affinity for albumin can impact how translatable an animal model to 
clinical settings is that depends on these factors.  The affinity with purified albumin at 
fixed concentrations exhibit no species dependences, however Ablavar binding in plasma 
serum albumin is greatest in humans (91%) compared to dogs, rats and mice (~60%) (i.e. 
binding for HSA > pig SA ~ rabbit SA > dog  SA ~ rat SA ~ mouse SA) (20).  These 
factors also impact the relaxivity among species of Ablavar binding in blood plasma 
(relaxivity in human > pig > dog ~ rabbit ~ rat ~ mouse) (20).  The differences in 
relaxivities of Ablavar across species have been attributed to the protein binding and 
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changes in the water exchange rate (29, 52, 53).  These factors limited the ability for 
quantification of albumin with the dreMR contrast vials.  The dreMR contrast vials used 
for the in vivo murine experiments contained rabbit serum albumin, and while the dreMR 
image showed contrast for only the targeted form of Ablavar with rabbit serum albumin, 
it was not possible to make appropriate quantification of the in vivo dreMR contrast due 
to the Ablavar pharmacokinetic species dependence. 
Ablavar has previously been used to study different disease states in murine 
models, including a glioma model to examine contrast enhancement and dose-
effectiveness of Ablavar compared to OptiMARK (gadoversetamide), an extracellular 
gadolinium-based MRI contrast agent (54), and an inflammatory lesion model to examine 
inflammatory changes in the kidneys that leads to lupus nephritis (53)  While the slow 
buildup and long vascular retention in tumours of Ablavar will lead to contrast 
enhancement, the use of a murine model will be less representative to predict the behavior 
of Ablavar in humans.  The ability for dreMR to detect the small and sensitive tumour 
and vascular changes in a murine model would however be scalable for humans, where 
the binding kinetics and relaxivities of Ablavar are greatest. 
4.2.2 Correlation with Histology and Visualizing Vascular 
Permeability 
An important area of any research using animal models is the correlation of the 
experimental images with histology and/or immunohistochemistry.  Due to the limited 
number of animals used thus far for the initial dreMR in vivo experiments, we were 
unable to perform appropriate histological characterization of the tumour and surrounding 
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tumour vascular environment.  Through further investigations of the albumin uptake of 
the tumour and surrounding vascular environment, and by observing and examining the 
differences of the tissue and tumour morphologies over time, we can begin to understand 
the changes in contrast observed with the dreMR images.  Angiogenesis plays an 
important role in the progression, growth, and metastasis of tumours (55).  The ability to 
measure, monitor, and understand their underlying molecular mechanisms can impact 
clinical therapies and patient outcomes.  Macromolecular contrast media can provide a 
means for imaging and quantifying angiogenesis and tumour permeability (56-60).  Due 
to the tendency of tumours to grow vascular networks quickly to feed their large energy 
demands, angiogenic vessels become permeable to macromolecular contrast media, 
where as non-diseased vessels do not (55, 61, 62).  Albumin has previously been shown 
to have an increased speciﬁcity to tumour development and response to therapies (24, 25, 
61, 63).  The ability for albumin to extravasate through permeable vessels into tumours 
makes it useful as a targetable molecule for tumour detection and characterization (61).  
Histological examinations of the albumin-Ablavar complex can be achieved using 
fluorescein microscopy of an avidin-biotin complex stain, which would yield a 
representation of the tumour and tumour vascular permeability (64, 65).  Dafni et. al. 
(2003) have previously used triply labeled albumin with biotin, rhodamine, and GdTPA 
to show the feasibility to detect by histology, flurescence, MRI, and inductively coupled 
plasma mass spectrometry the clearance of interstitial macromolecular plasma proteins 
after their extravasation from permeable blood vessels (66). 
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4.2.3 Imaging Technique Improvements 
The sensitivity of our study was limited primarily by the binding affinities and 
relaxivities of Ablavar to albumin, but also the ability to apply the appropriate field 
normalizations to the positive and negative T1-weigthed images to acquire the dreMR 
images.  Small image-offset errors can create imperfect normalizations and image 
registrations, reducing the final quality and accuracy of the dreMR image (4, 27, 67, 68).  
The inability to suppress non-targeted contrast media and native tissues would lead to 
image artifacts and result in artificial dreMR contrast.  The largest source causing image 
shifting errors was the occurrence of eddy currents induced by the fast switching of the 
field-cycling dreMR B0 insert coil.  The ability to compensate and correct for the presence 
of eddy currents eliminates the necessity to insert a delay time period between the 
preparatory stage of the pulse sequence and start of image acquisition, thereby increasing 
the available magnetization (created in the preparatory stage of the pulse sequence) for 
dreMR contrast.   
There are two available methods for eddy current compensation: (1) waveform 
pre-emphasis, and (2) dynamically adjusting the MRI system frequency.  Waveform pre-
emphasis requires additional hardware implementation, control and synchronization with 
the imaging pulse sequence, and high fidelity amplifiers (51).  Dynamically adjusting the 
system frequency requires the ability to modulate the pulse sequence before imaging 
(integrating another preparatory stage to the pulse sequence) to compensate and minimize 
the offset between the Lamor frequency and system reference frequency (67).  Both 
methods require prior knowledge of the temporal behavior of the eddy current for 
implementation.  Hoelscher et al. (67) have recently integrated an eddy current 
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compensation for dreMR imaging by dynamic phase modulation called eDREAM 
(Dynamic Reference Phase Modulation).  The approach uses a time varying phase that is 
added to the RF pulse and acquisition window to dynamically correct for the frequency 
offset.  An eddy current compensation with waveform pre-emphasis is currently under 
investigation to improve the dreMR imaging technique.  The approach uses a current-
controlled Helmoltz magnet pair wound around the diameter of the dreMR insert coil, 
which is dynamically synchronized to create a time-varying frequency offset at the end of 
the dreMR magnetic field shift (immediately before image acquisition) to compensate for 
the presence of the eddy current. 
 
4.3 Conclusion  
The development and application of dreMR for field-cycling contrast was 
demonstrated for in vivo imaging.  The overarching theme of this thesis was to extend the 
previous work of Alford et. al. (4) to develop and integrate dreMR towards an in vivo 
diseased animal model.  Field-cycling relaxometry techniques were used to measure and 
characterize the relaxivity of the targeting contrast agent Ablavar, demonstrating a 
relaxivity magnetic field dependence for only the targeted form with albumin.  New 
dreMR hardware and pulse sequences were synchronized and implemented to examine 
the Albavar-albumin binding to distinguish only the targeted form of the contrast agent.  
The dreMR imaging techniques greatly increases the ability to produce MR contrast 
localized to the sites where Ablavar was targeted with albumin.  Imaging with dreMR can 
produce dreMR contrast by way of two techniques: (1) dreMR single inversion 
subtraction technique, and (2) dreMR double inversion recovery.  Any targetable contrast 
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media that exhibits relaxivity magnetic field dependence can be utilized with dreMR 
imaging.  Development and understanding of current and emerging biomarkers can be 
enhanced by the increased specificity of dreMR imaging, which can lead to effective 
strategies for cancer staging through a new method of molecular imaging. 
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Appendix B – Animal Protocol 
 
 
Dr. Timothy Scholl 
Associate Scientist, Robarts Research Institute 
Assistant Professor, Department of Medical Biophysics 
Schulich School of Medicine and Dentistry 
Western University 
___________________________________________ 
 
Begin forwarded message: 
 
From:   
Subject: eSirius Notification - New Protocol Modification Has Been APPROVED2011-085::1 
Date: 8 August, 2012 4:34:05 PM EDT 
To:  
 
 
AUP Number: 2011-085 
PI Name: Scholl, Timothy 
AUP Title: Development of Metabolic Probes for Magnetic Resonance Imaging of Mouse Models of Cancer 
Official Notification of AUS Approval: A MODIFICATION to Animal Use Protocol 2011-085 has been approved. 
The holder of this Animal Use Protocol is responsible to ensure that all associated safety components (biosafety, 
radiation safety, general laboratory safety) comply with institutional safety standards and have received all 
necessary approvals. Please consult directly with your institutional safety officers. 
Submitted by: NTM, Support  
on behalf of the Animal Use Subcommittee 
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